Welcome to our dedicated page for Charles Riv Labs Intl news (Ticker: CRL), a resource for investors and traders seeking the latest updates and insights on Charles Riv Labs Intl stock.
Charles River Laboratories International, Inc. provides products and services used in drug discovery, early-stage development, safety assessment, and the manufacture of new therapies. Company news commonly covers results from its Research Models and Services, Discovery and Safety Assessment, and Manufacturing Solutions activities, along with updates on research models, nonclinical toxicology, microbial and biologics testing, and client demand trends.
Recurring developments also include digital pathology initiatives, AI-enabled workflow tools, rat in vitro fertility services, virtual control groups, and the Alternative Methods Advancement Project™, which relate to efficiency and reduced animal use where scientifically appropriate. Financial releases, investor presentations, governance updates, and portfolio changes are also recurring disclosure themes for CRL.
Charles River Laboratories (NYSE:CRL) has enhanced its Cell Therapy Flex Platform through a collaboration with Akadeum Life Sciences. The partnership integrates Akadeum's GMP-grade Human T Cell Leukopak Isolation Kit, featuring innovative Microbubble technology for cell separation.
The technology uses gravity-based isolation of T cells, offering a scalable and GMP-compliant solution that can be implemented without additional capital investment. The process can be performed directly in the apheresis bag, simplifying the workflow. This enhancement follows Charles River's recent integration of Akron Bio's Closed System Solutions line of liquid cytokines, further streamlining their cell therapy operations.
The Cell Therapy Flex Platform serves as an off-the-shelf solution for Cell Therapy Process Development, specifically validated for autologous CAR-T and TCR-T cell therapies, aiming to reduce risks, costs, and development timelines.Charles River Laboratories (NYSE: CRL) has joined the EASYGEN Consortium, an EU-backed initiative aimed at revolutionizing CAR-T cell therapy manufacturing. The consortium's primary goal is to develop an automated, hospital-based platform capable of producing personalized cell therapies within 24 hours.
Charles River will contribute by developing an ex vivo 3D screening platform that leverages their patient-derived xenograft (PDX) bank and high-content imaging to quickly identify safe and effective CAR-T cell candidates. This initiative addresses a critical need, as currently less than 20% of eligible patients receive CAR-T therapy due to complex manufacturing processes and supply chain limitations.
The EASYGEN Consortium, comprising 18 partners across 8 countries, aims to transform CAR-T production from weeks to days, making these life-saving treatments more accessible and affordable while reducing hospital staff workload.
Charles River Laboratories (NYSE: CRL) reported Q2 2025 results with revenue of $1.03 billion, a slight increase of 0.6% from Q2 2024. The company's GAAP EPS decreased to $1.06 from $1.74, while non-GAAP EPS increased 11.4% to $3.12.
Key segment performance showed mixed results: Research Models and Services (RMS) revenue grew 3.3% to $213.3M, Discovery and Safety Assessment (DSA) revenue declined 1.5% to $618.0M, and Manufacturing Solutions revenue increased 4.4% to $200.8M.
The company updated its 2025 guidance, now expecting organic revenue decline of (3.0)% to (1.0)% and non-GAAP EPS of $9.90-$10.30. Notably, the U.S. Department of Justice closed its investigation into the company's non-human primate supply chain.
[ "Non-GAAP EPS increased 11.4% to $3.12 per share", "Non-GAAP operating margin improved to 22.1% from 21.3%", "Manufacturing Solutions segment revenue grew 4.4% to $200.8M", "U.S. DOJ closed investigation into non-human primate supply chain", "Company raised full-year guidance for revenue and non-GAAP EPS" ]Charles River Laboratories (NYSE:CRL) announced plans to explore a strategic partnership with BioTech Social Inc. (BSI) to integrate crowdfunding capabilities into their Incubator (CIP) and Accelerator (CAP) Programs. The collaboration would enable early-stage cell and gene therapy developers to raise up to $5 million annually through BSI's BioTech Funding Portal.
The partnership aims to help biotech companies bridge the funding 'valley of death' by connecting them with non-accredited investors. This initiative builds upon Charles River's 2024-established CIP and CAP programs, which provide regulatory expertise, laboratory space, and equipment access. The companies plan to evaluate applications for the next cohort in conjunction with the upcoming European Cell and Gene Therapy Summit in September 2025.
Charles River Laboratories (NYSE: CRL) has entered into a strategic CDMO agreement with Elly's Team, a parent-led foundation focused on developing treatments for NEDAMSS, an ultra-rare genetic disorder. The collaboration leverages Charles River's Cell and Gene Therapy Accelerator Program to manufacture critical materials for Phase I clinical trials.
The partnership has already achieved significant success, with Elly becoming the first patient to receive IRF2BPL gene replacement therapy on April 3, 2025. The treatment received FDA approval in March 2025, just 13 months after diagnosis. Elly's Team utilized Charles River's eXpDNA™ platform and AAV Rep/Cap plasmids, reducing manufacturing efforts by up to 66 percent.
NEDAMSS, caused by IRF2BPL gene mutations, affects fewer than 150 cases worldwide and impacts motor skills, speech, eating, eyesight, and can cause seizures.
Charles River Laboratories (NYSE:CRL) has announced its second-quarter 2025 earnings release schedule. The company will release its financial results on Wednesday, August 6th, 2025, before market opening. A conference call to discuss the results will be held the same day at 9:00 a.m. ET.
Investors can access the live webcast through the company's Investor Relations website at ir.criver.com, where a replay will also be available after the call.
Charles River Laboratories (NYSE: CRL) and CHDI Foundation have announced the extension of their 20-year drug discovery partnership focused on developing treatments for Huntington's disease (HD). The collaboration, which began in 2005, will expand across Charles River's global network and integrate more deeply with CHDI's programs.
The extended partnership encompasses comprehensive services including integrated chemistry, biology, ADME for drug discovery, stem cell research, high-throughput screening, computational chemistry, pharmacology, and biomarker discovery. Over their collaboration, the partnership has yielded 15 composition of matter patent applications and supported research with more than 50 pharma and biotech companies.
The agreement includes data sharing with Charles River's learning algorithms, contributing to the industry's largest dataset while maintaining data protection standards.
Charles River Laboratories (NYSE: CRL) announced its upcoming presentation at the Bank of America 2025 Health Care Conference scheduled for Wednesday, May 14th at 8:40 a.m. PT (11:40 a.m. ET). During the presentation, management will discuss the company's strategic focus, business developments, and recent trends. The presentation will be accessible via live webcast through the Investor Relations section of Charles River's website at ir.criver.com. A replay will be available for at least two weeks after the event.